Altoida Awarded FDA Breakthrough Designation For Precision Neurology Software To Predict Alzheimer’s Disease

Altoida, Inc., announced that its precision neurology software used to diagnose Alzheimer’s disease and dementia was awarded Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). The non-invasive software device which measures and monitors neurocognitive function is backed by two decades of global research, and is now being evaluated to predict conversion from Mild Cognitive Impairment to Alzheimer’s disease with artificial intelligence.

The FDA Breakthrough Program and designation is designed to accelerate consumers’ access to innovative technologies that could provide more effective treatment or diagnosis. Under the program, Altoida will receive priority review and . . .